Were I a betting man, then, I'd bet that Merck will eclipse its previous annual high water mark of $10.6 million, this year.
We shall see -- but here's what they spent it on (in the most significant buckets):
. . . ..▲ Patent settlements (no specific bill).
▲ Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351).
▲ Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
▲ Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
▲ Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill).
▲ Supply chain safety (no specific bills).
▲ Access to over-the-counter medications (no specific bill); compounding (no specific bill).
▲ Deficit reduction (no specific bill); ADAP funding (no specific bill).
▲ Animal Drug User Fee Act (ADUFA). . . .
We will keep you posted -- but I will shortly write a new post -- of the connection between these figures, and Merck's recent India announcement. Fascinating, that.
No comments:
Post a Comment